8-K Announcements
6Material company update
May 1, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 23, 2026·SEC
Context Therapeutics Inc.(CNTX)Earnings, Financials & Key Ratios
CNTX•NASDAQ
$2.33
$214M mkt cap·Price updated May 7, 2026
AboutContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$0
- EBITDA-$40M-32.7%
- Net Income-$36M-35.2%
- EPS (Diluted)-0.38+17.4%
- ROE-46.39%+7.0%
- Debt/Equity0.00-19.5%
CNTX Key Insights
Context Therapeutics Inc. (CNTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 92 (top 8%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 62.9% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CNTX Price & Volume
Context Therapeutics Inc. (CNTX) stock price & volume — 10-year historical chart
Loading chart...
CNTX Growth Metrics
Context Therapeutics Inc. (CNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-45.57%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-14.8%
Return on Capital
10 Years-61.01%
5 Years-61.01%
3 Years-71.43%
Last Year-50.95%
CNTX Recent Earnings
Context Therapeutics Inc. (CNTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026EPS
$0.09
Est $0.12
+25.0%
Revenue
—
Q2 2026
Mar 23, 2026EPS
$0.14
Est $0.11
-27.3%
Revenue
—
Q2 2026
Mar 19, 2026EPS
$0.14
Est $0.11
-27.3%
Revenue
—
Est $1M
Q4 2025
Nov 5, 2025EPS
$0.10
Est $0.09
-11.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.09vs $0.12+25.0% | — |
| Q2 2026 | Mar 23, 2026 | $0.14vs $0.11-27.3% | — |
| Q2 2026 | Mar 19, 2026 | $0.14vs $0.11-27.3% | —vs $1M |
| Q4 2025 | Nov 5, 2025 | $0.10vs $0.09-11.1% | — |
Based on last 12 quarters of dataView full earnings history →
CNTX Peer Comparison
Context Therapeutics Inc. (CNTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 ONCO | 1.38M | 0.40 | -0.09 | -67.7% | -17.21% | -189.85% | 0.00 | |
 TPVG | 242.54M | 5.99 | 4.91 | 36.55% | -3.39% | 1.33 | ||
 AGIO | 1.64B | 27.53 | -3.87 | 48.03% | -6.4% | -34.11% | 0.05 | |
 SNDX | 1.81B | 20.54 | -6.24 | 6.28% | -112.01% | -256.66% | 5.36 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PRME | 562.42M | 3.12 | -2.31 | 55.28% | -62.42% | -188.82% | 0.96 |
Compare CNTX vs Peers
Context Therapeutics Inc. (CNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CNTX Income Statement
Context Therapeutics Inc. (CNTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 124.66K | 36.34K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -124.66K▲ 0% | -36.34K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.38M | 2.57M | 10.53M | 15.38M | 25.07M | 29.92M | 39.7M | 43.48M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.96M | 930.67K | 3.63M | 7.79M | 7.29M | 7.22M | 7.85M | 8.08M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 2.41M | 1.64M | 3.81M | 7.09M | 17.78M | 22.7M | 31.86M | 35.41M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 3.09M | 500K | 0 | 0 | 0 | 0 |
| Operating Income | -5.38M▲ 0% | -2.57M▲ 52.2% | -10.53M▼ 309.2% | -15.38M▼ 46.1% | -25.07M▼ 63.0% | -29.92M▼ 19.3% | -39.7M▼ 32.7% | -43.52M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 52.17% | -309.25% | -46.13% | -63.01% | -19.35% | -32.68% | - |
| EBITDA | -5.38M | -2.57M | -10.39M | -15.37M | -25.06M | -29.91M | -39.7M | -43.48M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | 52.17% | -304.07% | -47.91% | -63.03% | -19.36% | -32.73% | -37.51% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 9.27K | 12.04K | 10.88K | 0 | 40.41K |
| EBIT | -5.28M | -2.57M | -10.39M | -14.88M | -25.07M | -29.92M | -39.7M | -33.26M |
| Net Interest Income | -1.1M | -661K | -64.17K | 0 | 1.16M | 3.2M | 3.38M | 2.42M |
| Interest Income | 1.1K | 661 | 64 | 547.27K | 1.16M | 3.2M | 3.38M | 2.94M |
| Interest Expense | 1.1M | 661.22K | 64.24K | 547.27K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.01M | 9.22M | 68.95K | 545.26K | 1.11M | 3.2M | 3.58M | 3.29M |
| Pretax Income | -6.38M▲ 0% | 6.64M▲ 204.1% | -10.46M▼ 257.4% | -14.84M▼ 41.9% | -23.96M▼ 61.5% | -26.73M▼ 11.5% | -36.12M▼ 35.2% | -40.23M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.38M▲ 0% | 6.64M▲ 204.1% | -10.46M▼ 257.4% | -14.84M▼ 41.9% | -23.96M▼ 61.5% | -26.73M▼ 11.5% | -36.12M▼ 35.2% | -40.23M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | 204.07% | -257.39% | -41.88% | -61.53% | -11.52% | -35.17% | -45.57% |
| Net Income (Continuing) | -6.38M | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M | -40.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.68▲ 0% | -0.80▼ 17.6% | -3.69▼ 361.2% | -0.93▲ 74.8% | -1.50▼ 61.3% | -0.46▲ 69.3% | -0.38▲ 17.4% | -0.42▲ 0% |
| EPS Growth % | - | -17.65% | -361.25% | 74.8% | -61.29% | 69.33% | 17.39% | -14.8% |
| EPS (Basic) | -0.68 | 0.61 | -3.69 | -0.93 | -1.50 | -0.46 | -0.38 | - |
| Diluted Shares Outstanding | 10.96M | 10.96M | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M | 95.18M |
| Basic Shares Outstanding | 10.96M | 10.96M | 2.83M | 15.97M | 15.97M | 58.42M | 95.19M | 95.18M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CNTX Balance Sheet
Context Therapeutics Inc. (CNTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 239.61K | 349.71K | 51.26M | 37.85M | 16.05M | 97.9M | 68.35M | 58.52M |
| Cash & Short-Term Investments | 226.6K | 341.04K | 49.64M | 35.5M | 14.45M | 94.43M | 66M | 54.53M |
| Cash Only | 226.6K | 341.04K | 49.64M | 35.5M | 14.45M | 94.43M | 66M | 54.53M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 2.36M | 1.6M | 3.47M | 2.36M | 3.99M |
| Total Non-Current Assets | 33.94K | 117.63K | 50.39K | 112.28K | 15.52K | 230.78K | 140.07K | 342.28K |
| Property, Plant & Equipment | 0 | 0 | 0 | 79.53K | 15.52K | 230.78K | 140.07K | 342.28K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 50.39K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 33.94K | 117.63K | 0 | 32.75K | 0 | 0 | 0 | 200K |
| Total Assets | 273.55K▲ 0% | 467.34K▲ 70.8% | 51.31M▲ 10878.2% | 37.97M▼ 26.0% | 16.06M▼ 57.7% | 98.13M▲ 510.9% | 68.49M▼ 30.2% | 58.86M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 70.84% | 10878.25% | -26% | -57.69% | 510.9% | -30.2% | -90.26% |
| Total Current Liabilities | 24.11M | 9.55M | 3.03M | 3.21M | 4.19M | 2.75M | 8.02M | 6.53M |
| Accounts Payable | 2.07M | 2.71M | 1.83M | 936.33K | 2.38M | 1.45M | 2.53M | 2.47M |
| Days Payables Outstanding | - | - | - | - | - | - | 7.42K | 25.4K |
| Short-Term Debt | 21.84M | 5.88M | 0 | 0 | 0 | 0 | 112.06K | 160.06K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 85.53K | 853.51K | 661.3K | 941.7K | 5.38M | 3.91M |
| Current Ratio | 0.01x | 0.04x | 16.90x | 11.80x | 3.83x | 35.62x | 8.52x | 8.52x |
| Quick Ratio | 0.01x | 0.04x | 16.90x | 11.80x | 3.83x | 35.62x | 8.52x | 8.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 126K | 7.84M | 0 | 0 | 0 | 112.06K | 0 | 122.37K |
| Long-Term Debt | 0 | 69.04K | 0 | 0 | 0 | 0 | 0 | 122.37K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 112.06K | 0 | 73.55K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 126K | 7.77M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 24.23M | 17.39M | 3.03M | 3.21M | 4.19M | 2.86M | 8.02M | 6.66M |
| Total Debt | 21.84M | 5.95M | 0 | 55.08K | 0 | 219.38K | 112.06K | 282.42K |
| Net Debt | 21.62M | 5.61M | -49.64M | -35.44M | -14.45M | -94.21M | -65.88M | -54.25M |
| Debt / Equity | - | - | - | 0.00x | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 1.25x |
| Interest Coverage | -4.80x | -3.89x | -161.78x | -27.19x | - | - | - | - |
| Total Equity | -23.96M▲ 0% | -16.92M▲ 29.4% | 48.27M▲ 385.3% | 34.76M▼ 28.0% | 11.87M▼ 65.8% | 95.27M▲ 702.5% | 60.47M▼ 36.5% | 52.2M▲ 0% |
| Equity Growth % | - | 29.38% | 385.28% | -28% | -65.85% | 702.51% | -36.52% | -110.24% |
| Book Value per Share | -2.19 | -1.54 | 17.03 | 2.18 | 0.74 | 1.63 | 0.64 | 0.55 |
| Total Shareholders' Equity | -23.96M | -16.92M | 48.27M | 34.76M | 11.87M | 95.27M | 60.47M | 52.2M |
| Common Stock | 324 | 332 | 15.97K | 15.97K | 15.97K | 89.7K | 91.88K | 91.88K |
| Retained Earnings | -25.44M | -18.8M | -29.25M | -44.09M | -68.05M | -94.78M | -130.9M | -139.58M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNTX Cash Flow Statement
Context Therapeutics Inc. (CNTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.84M | -1.03M | -8.8M | -13.55M | -21.05M | -14.56M | -26.39M | -26.39M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 63.52% | -750.5% | -53.98% | -55.34% | 30.84% | -81.27% | -296.42% |
| Net Income | -6.38M | 6.64M | -10.46M | -14.84M | -23.96M | -26.73M | -36.12M | -40.23M |
| Depreciation & Amortization | 0 | 0 | 0 | 9.27K | 12.04K | 10.88K | 16.25K | 16.88K |
| Stock-Based Compensation | 775.25K | 219.25K | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M | 1.45M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.21M | -9.22M | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M | 10.35M |
| Working Capital Changes | 561.79K | 1.32M | -2.22M | -277.52K | 1.78M | -3.48M | 6.28M | 7.06M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 505.41K | 556.27K | -866.01K | -787.89K | 1.45M | -946K | 1.1M | 1.46M |
| Cash from Investing | 0 | 0 | -250K | -536.84K | 0 | -14.76M | -2.03M | -2.04M |
| Capital Expenditures | 0 | 0 | -250K | -536.84K | 0 | -7.32K | -33.95K | -2.04M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -14.75M | -2M | 0 |
| Cash from Financing | 1.96M | 1.15M | 58.39M | -102.07K | 0 | 109.29M | -15.27K | 0 |
| Debt Issued (Net) | 1.96M | 149.05K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 1M | 58.39M | -102.07K | 0 | 109.29M | -15.27K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -878.69K▲ 0% | 114.43K▲ 113.0% | 49.34M▲ 43020.5% | -14.14M▼ 128.7% | -21.05M▼ 48.9% | 79.98M▲ 480.0% | -28.43M▼ 135.6% | -34.82M▲ 0% |
| Free Cash Flow | -2.84M▲ 0% | -1.03M▲ 63.5% | -9.05M▼ 774.7% | -14.09M▼ 55.7% | -21.05M▼ 49.4% | -29.31M▼ 39.3% | -26.42M▲ 9.9% | -21.39M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 63.52% | -774.67% | -55.66% | -49.42% | -39.27% | 9.87% | -40.15% |
| FCF per Share | -0.26 | -0.09 | -3.19 | -0.88 | -1.32 | -0.50 | -0.28 | -0.28 |
| FCF Conversion (FCF/Net Income) | 0.44x | -0.16x | 0.84x | 0.91x | 0.88x | 0.54x | 0.73x | 0.53x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CNTX Key Ratios
Context Therapeutics Inc. (CNTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -66.71% | -35.74% | -102.79% | -49.89% | -46.39% | -59.95% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | 1098.69% |
| Debt / Equity | - | - | 0.00x | - | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -3.89x | -161.78x | -27.19x | - | - | - | - |
| FCF Conversion | -0.16x | 0.84x | 0.91x | 0.88x | 0.54x | 0.73x | 0.53x |
CNTX SEC Filings & Documents
Context Therapeutics Inc. (CNTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CNTX Frequently Asked Questions
Context Therapeutics Inc. (CNTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Context Therapeutics Inc. (CNTX) grew revenue by 0.0% over the past year. Growth has been modest.
Context Therapeutics Inc. (CNTX) reported a net loss of $40.2M for fiscal year 2025.
Dividend & Returns
Context Therapeutics Inc. (CNTX) has a return on equity (ROE) of -46.4%. Negative ROE indicates the company is unprofitable.
Context Therapeutics Inc. (CNTX) had negative free cash flow of $21.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More CNTX
Context Therapeutics Inc. (CNTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates